Ilika hails year of important achievements for solid-state battery technologies

Ilika PLC reported full-year results to April 30, highlighting significant technical and commercial progress across its Stereax and Goliath solid-state battery technologies. Key advancements include the transfer of Stereax miniature battery manufacturing to Cirtec Medical in the US, with 21 medical device customers and M300 samples expected this year, and the validation of Goliath P1 prototypes, a 50Ah prototype with BMW and Fortescue, and 21 OEM evaluation agreements. While recording £1.1 million turnover and a £5.2 million adjusted EBITDA loss, Ilika strengthened its balance sheet with a post-period £4.2 million fundraising and a £1.25 million grant, with the CEO projecting future product-related revenue growth.

Analysis

Ilika PLC is demonstrating a clear transition from research and development to commercialization, marked by significant operational milestones across its two core solid-state battery platforms. For its Stereax miniature batteries, the manufacturing transfer to US partner Cirtec Medical and engagement with 21 customers for medical device applications signal a tangible path to revenue, with the planned delivery of M300 commercial samples this year serving as a key near-term catalyst. Simultaneously, the Goliath program for electric vehicles has advanced with the validation of P1 prototypes, the development of a 50Ah prototype in collaboration with major industry players BMW and Fortescue, and 21 evaluation agreements with OEMs. These technical achievements, however, are set against the financial reality of a pre-revenue technology firm: turnover was just £1.1 million against an adjusted EBITDA loss of £5.2 million. The company's liquidity has been shored up by a post-period £4.2 million fundraising and a £1.25 million grant, extending its operational runway as it works to convert these technical and commercial engagements into meaningful product-related revenue.

Key Decisions for Investors

• Investors should weigh the significant operational de-risking, evidenced by partnerships with BMW and Cirtec and 42 total customer evaluation agreements, against the company's current cash burn and reliance on external funding.
• The successful delivery of commercial Stereax M300 samples this year represents a critical validation point and a key catalyst for near-term revenue generation; any delays could significantly impact sentiment and the company's financial position.
• Monitor the conversion rate of evaluation agreements into firm commercial orders for both the Stereax and Goliath programs, as this will be the primary indicator of market acceptance and the company's ability to scale production and achieve profitability.